MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas
Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Stefania Dell’Oro(Vita-Salute San Raffaele University), Marco Foppoli(Vita-Salute San Raffaele University), Massimo Bernardi(Vita-Salute San Raffaele University), Alba A. Brandes(Vita-Salute San Raffaele University), A. Tosoni(Vita-Salute San Raffaele University), Mauro Montanari(Vita-Salute San Raffaele University), Monica Balzarotti(Vita-Salute San Raffaele University), Michele Spina(Vita-Salute San Raffaele University), Fiorella Ilariucci(Vita-Salute San Raffaele University), Francesco Zaja(Vita-Salute San Raffaele University), Caterina Stelitano(Vita-Salute San Raffaele University), Flavio Bobbio(Vita-Salute San Raffaele University), Gaetano Corazzelli(Vita-Salute San Raffaele University), Luca Baldini(Vita-Salute San Raffaele University), Maurilio Ponzoni(Vita-Salute San Raffaele University), Piero Picozzi(Vita-Salute San Raffaele University), F. Caligaris Cappio(Vita-Salute San Raffaele University), Michele Reni(Vita-Salute San Raffaele University)
Cited by 94
Abstract
The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76% after MATILDE and 83% after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low- to intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG] score). Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 +/- 7%) was obtained.
Related Papers
No related papers found
Powered by citation graph analysis